Pure Encapsulations – owned by Nestlé – will now sell CBD soft gel formulations which use the patented VESIsorb drug delivery system for improved absorption and bioavailability.
The first large-scale production was completed and delivered earlier this month using only European resources, including cultivation and extraction of the hemp biomass in Slovenia and drug delivery technology and soft gel capsule production in Switzerland.
The first product that Pure Encapsulations is launching in Europe is a soft gel capsule with a science-backed two-to-one ratio of CBD (cannabidiol) to BCP (beta-caryophyllene) from broad spectrum hemp extract that utilises the VESIsorb delivery system.
“We are extremely proud to expand our relationship with Nestlé’s healthcare professional brands into Europe after their success in the U.S. market this past year,” said Jesse Lopez, CEO and founder of Geocann.
“Their leadership team’s validation of science-backed and clinically-proven hemp products is an important milestone for our industry and provides exceptional credibility to the therapeutic benefits of cannabinoids formulated with VESIsorb.”
Dr. Barry Ritz, Chief Science Officer at Pure Encapsulations, adds: “Our partnership is built on a relentless effort to ensure these are the most science-backed CBD products in the world, setting the benchmark for what consumers expect and healthcare professionals demand.”
VESIsorb
The CBG soft gel products utilise the VESIsorb delivery system developed by Swiss company Vesifact, a spin-off of the Federal Institute of Technology in Zurich. The delivery system is described as a self-assembling colloidal droplet delivery system, and is covered by multiple patents.